{
  "validation_results": [
    {
      "drug": "Benazepril",
      "disease": "hypertension",
      "evidence": "FDA_APPROVED",
      "notes": "ACE inhibitor, standard first-line treatment",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/1720384/",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019851s038lbl.pdf"
      ]
    },
    {
      "drug": "Doxorubicin",
      "disease": "breast cancer",
      "evidence": "FDA_APPROVED",
      "notes": "Standard chemotherapy, FDA approved for breast cancer",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/38884850/",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC12173247/"
      ]
    },
    {
      "drug": "Azathioprine",
      "disease": "rheumatoid arthritis",
      "evidence": "ESTABLISHED_TREATMENT",
      "notes": "DMARD, used clinically though second-line due to toxicity",
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC8406472/",
        "https://pubmed.ncbi.nlm.nih.gov/11034720/"
      ]
    },
    {
      "drug": "Empagliflozin",
      "disease": "heart failure",
      "evidence": "FDA_APPROVED",
      "notes": "FDA approved 2021 for HF regardless of ejection fraction",
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC9887434/",
        "https://pubmed.ncbi.nlm.nih.gov/35228754/"
      ]
    },
    {
      "drug": "Rivastigmine",
      "disease": "parkinson disease",
      "evidence": "FDA_APPROVED",
      "notes": "FDA approved for Parkinson's disease dementia, NEJM landmark trial",
      "sources": [
        "https://www.nejm.org/doi/full/10.1056/NEJMoa041470",
        "https://pubmed.ncbi.nlm.nih.gov/15590953/"
      ]
    },
    {
      "drug": "Tezepelumab",
      "disease": "asthma",
      "evidence": "FDA_APPROVED",
      "notes": "FDA approved Dec 2021, first-in-class anti-TSLP",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/35184265/",
        "https://www.nature.com/articles/d41573-022-00013-5"
      ]
    },
    {
      "drug": "Lecanemab",
      "disease": "alzheimer disease",
      "evidence": "FDA_APPROVED",
      "notes": "FDA approved Jan 2023, first approved amyloid-clearing therapy",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/36449413/",
        "https://www.nejm.org/doi/full/10.1056/NEJMoa2212948"
      ]
    },
    {
      "drug": "Losartan",
      "disease": "heart failure",
      "evidence": "ESTABLISHED_TREATMENT",
      "notes": "ARB, proven efficacy in HF trials (HEAAL study)",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/19922995/",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC6823214/"
      ]
    },
    {
      "drug": "Paclitaxel",
      "disease": "rheumatoid arthritis",
      "evidence": "RESEARCH_SUPPORT",
      "notes": "Preclinical evidence: anti-angiogenic, synoviocyte inhibition. Phase I mentioned but not approved",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/7518753/",
        "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.714566/full"
      ]
    },
    {
      "drug": "Naproxen",
      "disease": "type 2 diabetes",
      "evidence": "WEAK_SUPPORT",
      "notes": "Some NSAID data on glucose, salsalate shows effect, but naproxen not indicated",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/27194069/",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC9181422/"
      ]
    },
    {
      "drug": "Gentamicin",
      "disease": "type 2 diabetes",
      "evidence": "NO_EVIDENCE",
      "notes": "FALSE POSITIVE - Actually INHIBITS insulin release! Nephrotoxic antibiotic.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/2408593/"
      ]
    },
    {
      "drug": "Atezolizumab",
      "disease": "lung cancer",
      "evidence": "FDA_APPROVED",
      "notes": "FDA approved for NSCLC (adjuvant, first-line, SCLC)",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/36951523/",
        "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression"
      ]
    },
    {
      "drug": "Spironolactone",
      "disease": "heart failure",
      "evidence": "FDA_APPROVED",
      "notes": "MRA, standard HF treatment, RALES trial showed mortality reduction",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/39584253/",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC6312809/"
      ]
    },
    {
      "drug": "Cisplatin",
      "disease": "lung cancer",
      "evidence": "STANDARD_TREATMENT",
      "notes": "Backbone of platinum-based chemotherapy for NSCLC",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/26866673/",
        "https://www.ncbi.nlm.nih.gov/books/NBK547695/"
      ]
    },
    {
      "drug": "Quetiapine",
      "disease": "parkinson disease",
      "evidence": "OFF_LABEL_USE",
      "notes": "Used clinically as first-line for PD psychosis but not FDA approved (pimavanserin is)",
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC3002640/",
        "https://pubmed.ncbi.nlm.nih.gov/27056066/"
      ]
    },
    {
      "drug": "Thiamine",
      "disease": "alzheimer disease",
      "evidence": "RESEARCH_SUPPORT",
      "notes": "Thiamine deficiency linked to AD-like changes, clinical trials ongoing with benfotiamine",
      "sources": [
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC4846521/",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC11712508/"
      ]
    }
  ],
  "metrics": {
    "total_validated": 16,
    "fda_approved_count": 11,
    "fda_approved_pct": 0.6875,
    "research_support_count": 4,
    "research_support_pct": 0.25,
    "false_positive_count": 1,
    "false_positive_pct": 0.0625,
    "clinically_validated_precision": 0.6875,
    "biologically_plausible_precision": 0.9375
  }
}